Diaceutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ryan Keeling
Chief executive officer
UK£282.5k
Total compensation
| CEO salary percentage | 95.2% |
| CEO tenure | less than a year |
| CEO ownership | 3.5% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£3m |
| Mar 31 2024 | n/a | n/a | -UK£2m |
| Dec 31 2023 | UK£282k | UK£269k | -UK£2m |
| Sep 30 2023 | n/a | n/a | -UK£870k |
| Jun 30 2023 | n/a | n/a | UK£6k |
| Mar 31 2023 | n/a | n/a | UK£365k |
| Dec 31 2022 | UK£334k | UK£252k | UK£724k |
| Sep 30 2022 | n/a | n/a | UK£427k |
| Jun 30 2022 | n/a | n/a | UK£129k |
| Mar 31 2022 | n/a | n/a | UK£345k |
| Dec 31 2021 | UK£231k | UK£220k | UK£561k |
| Sep 30 2021 | n/a | n/a | -UK£294k |
| Jun 30 2021 | n/a | n/a | -UK£1m |
| Mar 31 2021 | n/a | n/a | -UK£443k |
| Dec 31 2020 | UK£225k | UK£215k | UK£263k |
| Sep 30 2020 | n/a | n/a | UK£2m |
| Jun 30 2020 | n/a | n/a | UK£3m |
| Mar 31 2020 | n/a | n/a | UK£2m |
| Dec 31 2019 | UK£236k | UK£175k | UK£398k |
| Sep 30 2019 | n/a | n/a | UK£124k |
| Jun 30 2019 | n/a | n/a | -UK£151k |
| Mar 31 2019 | n/a | n/a | UK£241k |
| Dec 31 2018 | UK£78k | n/a | UK£632k |
Compensation vs Market: Ryan's total compensation ($USD349.68K) is about average for companies of similar size in the German market ($USD465.04K).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Keeling (42 yo)
less than a year
Tenure
UK£282,494
Compensation
Mr. Ryan Keeling serves as Executive Director of Diaceutics PLC, he joined the company in 2006 and serves as Chief Executive Officer since January 1, 2024 and is responsible for the innovation strategy for...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | less than a year | UK£310.99k | 18.65% € 25.8m | |
| CEO & Director | less than a year | UK£282.49k | 3.54% € 4.9m | |
| CFO & Director | 2.8yrs | UK£193.05k | 0.077% € 106.6k | |
| Vice President of Scientific & Medical Services | less than a year | no data | no data | |
| General Counsel | 3yrs | no data | no data | |
| Vice President of Marketing | less than a year | no data | no data | |
| Interim VP of Sales | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Data Officer? & Executive Director | less than a year | no data | 0.68% € 945.3k | |
| Chief Precision Medicine Officer | 6yrs | no data | 0.30% € 409.7k | |
| Chief Commercial Officer | 2yrs | no data | no data | |
| VP & Chief of Staff | less than a year | no data | no data |
1.0yrs
Average Tenure
42yo
Average Age
Experienced Management: 7DC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | less than a year | UK£310.99k | 18.65% € 25.8m | |
| CEO & Director | no data | UK£282.49k | 3.54% € 4.9m | |
| CFO & Director | 2.8yrs | UK£193.05k | 0.077% € 106.6k | |
| Chief Data Officer? & Executive Director | less than a year | no data | 0.68% € 945.3k | |
| Senior Independent Director | 1.3yrs | UK£15.00k | 0.087% € 120.6k | |
| Non-Executive Director | less than a year | no data | no data |
0.3yrs
Average Tenure
47.5yo
Average Age
Experienced Board: 7DC's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 09:37 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Diaceutics PLC is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hayley Palmer | Canaccord Genuity |
| Colin Smith | Capital Access Group |
| Oliver Juggins | Capital Access Group |